Latest Tax Refunds News

FBR has cut its annual loss dramatically and moved its first Mantis welding robot into commissioning, but year-end cash of just A$27,814 leaves the company dependent on fundraising, tax funding and successful delivery. Its audited accounts flag a material uncertainty over whether the robotics developer can continue as a going concern.

Norwood Systems delivered higher revenue, record customer receipts and a sharp reduction in operating cash outflow in FY2026. But the ASX-listed AI voice company remains loss-making, cash-light and subject to a material going-concern uncertainty.

CONNEQT Health delivered sharp FY26 revenue growth and reduced its statutory loss as Pulse sales and clinical subscriptions expanded. But the ASX-listed medtech group ended the year with negative net assets, heavy cash burn and a material uncertainty over its ability to continue as a going concern.

Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.

EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.

Legacy Minerals enters FY2027 with a larger Mt Carrington resource, a positive preliminary development study and fresh drilling underway, but the proposed mine still requires substantial funding. The ASX-listed explorer reported a A$1.85 million FY2026 loss and held A$6.07 million in cash at year-end.

BluGlass has agreed an A$8.0 million R&D-backed loan with Rockford, refinancing its existing Radium facility and adding about A$5.5 million of liquidity. The funding gives the laser developer more room to scale, but carries a 16.5% interest rate and repayment obligations tied to future tax refunds.

HITIQ has secured a $1.5 million R&D tax incentive loan facility and drawn half the available funding, providing immediate liquidity while adding interest-bearing debt. The arrangement with a related party also puts shareholder approval of proposed security in focus.

Gold Hydrogen has advanced Ramsay drilling, testing and commercial studies, but its annual report carries a material uncertainty over the company’s ability to continue as a going concern. The pre-revenue explorer ended FY2026 with $9.42 million in cash after spending heavily on exploration.

Marquee Resources has received a $549,122 R&D tax refund, adding non-dilutive cash ahead of planned drilling at its Yindi Lithium and Gold Project in Western Australia. The filing improves near-term financial flexibility but does not disclose the company’s post-refund cash balance or drilling budget.

Michael Hill International reported a 1.9% revenue increase to $655.7 million in FY26, with comparable EBIT up 57% to $24 million and net profit soaring 376%. The company restored dividends and announced a Chair succession.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.